丹麦一般人群中JAK2 V617F与钙网蛋白突变的患病率及表型
在丹麦一般郊区人群研究中,对19958名参与者用微滴数字PCR筛查JAK2 V617F与CALR突变,突变阳性率为3.2%,其中16人(2.5%)基线时患有骨髓增殖性肿瘤(MPN)。JAK2 V617F和CALR的人群患病率分别为3.1%(CI 2.8-3.3)和0.16%(CI 0.11-0.23),年龄增长、吸烟和饮酒是突变的危险因素。JAK2 V617F阳性者无论是否患MPN,现患静脉血栓栓塞的比值均升高;突变阳性者血细胞计数高于非突变者,42%无MPN的突变阳性者至少一项血细胞计数升高,80人(13%)的血细胞计数符合现行MPN诊断标准。
要点
- 丹麦一般人群JAK2 V617F患病率为3.1%(CI 2.8-3.3),CALR患病率为0.16%(CI 0.11-0.23)。
- JAK2 V617F阳性者(伴或不伴MPN)现患静脉血栓栓塞的比值升高。
- 42%无MPN的突变阳性者至少一项血细胞计数升高,13%符合现行MPN诊断标准。
核心结论
- 本文报告了CALR的人群患病率,并发现JAK2 V617F患病率比敏感性较低的方法高3至30倍。
- 血细胞计数升高的突变阳性非MPN者提示人群中可能存在MPN诊断不足。
研究设计与样本
- 研究纳入丹麦一般郊区人群研究2010-2013年登记的19958名合格参与者,用微滴数字聚合酶链反应筛查JAK2 V617F和CALR突变。
- 645名突变阳性者中,613名为JAK2 V617F阳性,32名为CALR阳性;16人(2.5%)基线时患有MPN。
主要发现
- JAK2 V617F和CALR的人群患病率分别为3.1%(CI 2.8-3.3)和0.16%(CI 0.11-0.23)。
- 年龄增长、吸烟和饮酒是突变的危险因素。
- JAK2 V617F阳性者伴或不伴MPN,现患静脉血栓栓塞的比值均升高。
- 每增加1%等位基因负荷,MPN诊断的比值比为1.14(95% CI 1.09-1.18;P=1.6×10^-10)。
- 突变阳性者血细胞计数高于非突变者,42%无MPN的突变阳性者至少一项血细胞计数升高,80人(13%)的血细胞计数符合现行MPN诊断标准。
关键数值与推荐
- JAK2 V617F人群患病率为3.1%(CI 2.8-3.3),CALR人群患病率为0.16%(CI 0.11-0.23)。
- 每1%等位基因负荷对应的MPN诊断比值比为1.14(95% CI 1.09-1.18;P=1.6×10^-10)。
- 42%无MPN的突变阳性者至少一项血细胞计数升高;80人(13%)的血细胞计数符合现行MPN诊断标准。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The JAK2 V617F and calreticulin mutations (CALR) are frequent within myeloproliferative neoplasms (MPNs). JAK2 V617F has been detected in the general population, but no studies have previously investigated the CALR prevalence. Thus, we aimed to determine the CALR and JAK2 V617F population prevalence and assess the biochemical profile and lifestyle factors in mutation-positive individuals with and without MPN. 19 958 eligible participants, enrolled from 2010-2013, from the Danish General Suburban Population Study were screened for JAK2 V617F and CALR by droplet digital polymerase chain reaction with (3.2%) mutation positives of which 16 (2.5%) had MPN at baseline. Of 645 participants, 613 were JAK2 V617F positive, and 32 were CALR positive, corresponding to a population prevalence of 3.1% (confidence interval [CI], 2.8-3.3) and 0.16% (CI, 0.11-0.23), respectively. Increasing age, smoking, and alcohol were risk factors for the mutations. JAK2 V617F positives with and without MPN presented elevated odds for prevalent venous thromboembolism. The odds ratio for a diagnosis of MPN per percentage allele burden was 1.14 (95% CI, 1.09-1.18; P = 1.6 × 10-10). Mutation positives displayed higher blood cell counts than nonmutated participants, and 42% of mutation positives without MPN presented elevation of ≥1 blood cell counts; 80 (13%) even presented blood cell counts in accordance with current MPN diagnostic criteria. In conclusion, we present a novel population prevalence of CALR and a JAK2 V617F prevalence that is 3 to 30 times higher compared with less sensitive methods. Mutation-positive non-MPNs with elevated blood cell counts raise concerns of MPN underdiagnosis in the population.
引用
- Cordua S, Kjaer L, Skov V, et al. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019. PMID: 31217187. doi:10.1182/blood.2019001113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。